Skip to main content

Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.

Publication ,  Journal Article
Cook, AL; Kishnani, PS; Carboni, MP; Kanter, RJ; Chen, YT; Ansong, AK; Kravitz, RM; Rice, H; Li, JS
Published in: Genet Med
May 2006

PURPOSE: Infantile Pompe disease is caused by deficiency of lysosomal acid alpha-glucosidase. Trials with recombinant human acid alpha-glucosidase enzyme replacement therapy (ERT) show a decrease in left ventricular mass and improved function. We evaluated 24-hour ambulatory electrocardiograms (ECGs) at baseline and during ERT in patients with infantile Pompe disease. METHODS: Thirty-two ambulatory ECGs were evaluated for 12 patients with infantile Pompe disease from 2003 to 2005. Patients had a median age of 7.4 months (2.9-37.8 months) at initiation of ERT. Ambulatory ECGs were obtained at determined intervals and analyzed. RESULTS: Significant ectopy was present in 2 of 12 patients. Patient 1 had 211 and 229 premature ventricular contractions (0.2% of heart beats) at baseline and at 11.5 weeks of ERT, respectively. Patient 2 had 10,445 premature ventricular contractions (6.7% of heart beats) at 11 weeks of therapy. CONCLUSION: Infantile Pompe disease may have preexisting ectopy; it may also develop during the course of ERT. Therefore, routinely monitoring patients using 24-hour ambulatory ECGs is useful. Periods of highest risk may be early in the course of ERT when there is a substantial decrease in left ventricular mass and an initial decrease in ejection fraction.

Duke Scholars

Published In

Genet Med

DOI

ISSN

1098-3600

Publication Date

May 2006

Volume

8

Issue

5

Start / End Page

313 / 317

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Ventricular Premature Complexes
  • Recombinant Proteins
  • Male
  • Infant
  • Humans
  • Heart Conduction System
  • Glycogen Storage Disease Type II
  • Glycogen
  • Genetics & Heredity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cook, A. L., Kishnani, P. S., Carboni, M. P., Kanter, R. J., Chen, Y. T., Ansong, A. K., … Li, J. S. (2006). Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. Genet Med, 8(5), 313–317. https://doi.org/10.1097/01.gim.0000217786.79173.a8
Cook, Amanda L., Priya S. Kishnani, Michael P. Carboni, Ronald J. Kanter, Y. T. Chen, Annette K. Ansong, Richard M. Kravitz, Henry Rice, and Jennifer S. Li. “Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.Genet Med 8, no. 5 (May 2006): 313–17. https://doi.org/10.1097/01.gim.0000217786.79173.a8.
Cook AL, Kishnani PS, Carboni MP, Kanter RJ, Chen YT, Ansong AK, et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. Genet Med. 2006 May;8(5):313–7.
Cook, Amanda L., et al. “Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.Genet Med, vol. 8, no. 5, May 2006, pp. 313–17. Pubmed, doi:10.1097/01.gim.0000217786.79173.a8.
Cook AL, Kishnani PS, Carboni MP, Kanter RJ, Chen YT, Ansong AK, Kravitz RM, Rice H, Li JS. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. Genet Med. 2006 May;8(5):313–317.

Published In

Genet Med

DOI

ISSN

1098-3600

Publication Date

May 2006

Volume

8

Issue

5

Start / End Page

313 / 317

Location

United States

Related Subject Headings

  • alpha-Glucosidases
  • Ventricular Premature Complexes
  • Recombinant Proteins
  • Male
  • Infant
  • Humans
  • Heart Conduction System
  • Glycogen Storage Disease Type II
  • Glycogen
  • Genetics & Heredity